Jerry Durso, Intercept CEO
FDA adds new 'do not use' note to Intercept's Ocaliva label after a slew of side effect reports in cirrhosis patients
Intercept has seen nothing but hard times the past year after a highly touted swing at NASH fell flat at the FDA’s feet last summer …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
